Cardiac Resynchronization: Race, Age, Geography Matter, Study Shows

August 12, 2008

(PhysOrg.com) -- Race, age, and geography appear to play important roles in who receives cardiac resynchronization therapy (CRT), a proven treatment for some patients with heart failure, say researchers at Duke Clinical Research Institute (DCRI).

"We looked at figures nationwide, and we found that use of the therapy was extremely variable," says Dr. Jonathan Piccini, M.D., a cardiologist at Duke University Medical Center and the lead author of the study. "Basically, a lot of people who should be getting the therapy aren't, and some of the people who are getting it may not need it."

The study, appearing in the journal Circulation, showed that only a small percentage of patients with severe heart dysfunction received the device, and those who did were disproportionately younger, white men. Researchers also found that in about 10 percent of the time, doctors who prescribed CRT did not follow published recommended clinical guidelines.

Study leaders say the findings reveal a troubling picture. It has been estimated that anywhere from a third to a half of all patients hospitalized with heart failure could benefit from CRT. Previous studies have shown that when CRT is used with optimal medical treatment, it can dramatically reduce the need for repeated hospitalization and lower the risk of untimely death. Two years ago, the American College of Cardiology/American Heart Association strongly recommended CRT therapy for selected patients with severe heart failure. But until now, it has not been known if the therapy is being used, or if it is being used appropriately.

To find out, investigators examined the records of nearly 34,000 admissions for heart failure from January 2005 to September 2007 in 228 hospitals enrolled in the American College of Cardiology/ American Heart Association's "Get with the Guidelines" program, a project designed to improve the quality of heart failure care nationwide.

The researchers tracked which patients came into the hospital with CRT in place, and those who had it when they left. They found that the use of the therapy varied significantly, with some hospitals not using it at all, while others hospitals showed up to 23 percent of potentially eligible patients were receiving the treatment.

They also found that blacks were less likely than whites to receive CRT – even though blacks are twice as likely to suffer from heart failure as whites. In addition, researchers discovered that older, sicker patients and those who lived in the Northeast were less likely to receive CRT than were younger patients who lived in other parts of the country.

"Our findings parallel previous studies evaluating adoption of new medical technology in that they show racial disparity in who is receiving the newest therapies," says Piccini. "In contrast to previous studies, however, we didn't find any gender gap in the use of CRT." The study showed that roughly equal numbers of men and women received CRT for the first time during their hospital stay.

Cardiac resynchronization involves implanting a specialized pacemaker in the upper part of the chest and running leads into the heart to correct an electrical conduction problem that allows the two ventricles to beat separately, instead of together. In "resetting" the electrical system, CRT enables the ventricles to pump in tandem again.

Clinical guidelines recommend that CRT be reserved for patients with left ventricular ejection fractions of 35 percent or less. An ejection fraction is a numerical measure reflecting how much blood leaves the ventricle with each heartbeat. But the study found that in about 10 percent of the time, physicians were prescribing CRT for patients who had ejection fractions above 35 percent.

"We will be watching these trends closely," says Adrian Hernandez, M.D., a cardiologist at Duke and senior author of the study. "CRT is an effective therapy for many patients, and this study suggests clinically practice varies greatly compared to what it should be, according to recommended guidelines."

The study was funded by the American Heart Association.

Provided by Duke University

Explore further: Abbott: New pacemaker firmware update addresses vulnerabilities

Related Stories

Abbott: New pacemaker firmware update addresses vulnerabilities

September 1, 2017
(Tech Xplore)—Regarding cybersecurity vulnerabilities identified in Abbott's (formerly St. Jude Medical's) implantable cardiac pacemakers, the US Food and Drug Administration issued a firmware update dated August 29.

Heart muscle disease patients benefit from defibrillator

September 4, 2017
Some heart disease patients who are treated with cardiac resynchronisation therapy (CRT) would live longer and have fewer hospital admissions if they also received a defibrillator, concludes a team of researchers led by Aston ...

Long-term survival rates double previous estimates for locally advanced lung cancer

September 25, 2017
Long-term results of a phase III clinical trial indicate that survival rates for patients receiving chemoradiation for unresectable, locally advanced non-small cell lung cancer (NSCLC) may be more than twice as high as previous ...

Heart Failure: Targeting the right patients for CRT-D

May 22, 2011
Patients with dyssynchronous yet viable ventricles are most likely to benefit from cardiac resynchronization therapy combined with defibrillation, concludes the latest analysis of the MADIT CRT trial. The CRT-MADIT-CRT trial ...

Detailed assessment of heart failure identifies patients needing pacemaker treatment (CRT)

June 10, 2014
By measuring how synchronised the heart chambers work together, it is possible to identify which patients with heart failure who benefit from pacemaker therapy, and which ones who do not. This is presented in a thesis to ...

CRT consensus set to standardize and improve care for patients worldwide

August 28, 2012
Recommendations for the practical management of CRT patients have been set out for the first time in an international consensus statement on cardiac resynchronization therapy (CRT) in heart failure.

Recommended for you

Researchers discover key signaling protein for muscle growth

November 20, 2017
Researchers at the University of Louisville have discovered the importance of a well-known protein, myeloid differentiation primary response gene 88 (MyD88), in the development and regeneration of muscles. Ashok Kumar, Ph.D., ...

New breast cell types discovered by multidisciplinary research team

November 20, 2017
A joint effort by breast cancer researchers and bioinformaticians has provided new insights into the molecular changes that drive breast development.

Brain cell advance brings hope for Creutzfeldt-Jakob disease

November 20, 2017
Scientists have developed a new system to study Creutzfeldt-Jakob disease in the laboratory, paving the way for research to find treatments for the fatal brain disorder.

Hibernating ground squirrels provide clues to new stroke treatments

November 17, 2017
In the fight against brain damage caused by stroke, researchers have turned to an unlikely source of inspiration: hibernating ground squirrels.

Age and gut bacteria contribute to multiple sclerosis disease progression

November 17, 2017
Researchers at Rutgers Robert Wood Johnson Medical School published a study suggesting that gut bacteria at young age can contribute to multiple sclerosis (MS) disease onset and progression.

Molecular guardian defends cells, organs against excess cholesterol

November 16, 2017
A team of researchers at the Harvard T. H. Chan School of Public Health has illuminated a critical player in cholesterol metabolism that acts as a molecular guardian in cells to help maintain cholesterol levels within a safe, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.